CRISPRi, for example might be used to target dCas9-repressor fusion proteins to the DMPK promoter to impair initiation of transcription, thereby reducing expanded DMPK RNA levels (compare the use of CRISPRa in FXS [53]). This evidence concerns the gene DMPK and fragile X syndrome.